These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 22932665)
1. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665 [TBL] [Abstract][Full Text] [Related]
2. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699 [TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160 [TBL] [Abstract][Full Text] [Related]
6. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473 [TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells. Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085 [TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443 [TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
11. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239 [TBL] [Abstract][Full Text] [Related]
12. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Vekaria PH; Kumar A; Subramaniam D; Dunavin N; Vallurupalli A; Schoenen F; Ganguly S; Anant S; McGuirk JP; Jensen RA; Rao R Leukemia; 2019 Jul; 33(7):1675-1686. PubMed ID: 30664664 [TBL] [Abstract][Full Text] [Related]
13. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119 [TBL] [Abstract][Full Text] [Related]
14. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Hayden A; Johnson PW; Packham G; Crabb SJ Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284 [TBL] [Abstract][Full Text] [Related]
18. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170 [TBL] [Abstract][Full Text] [Related]
19. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446 [TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]